Inflammatory and Genetic Predictors of Cognitive and Emotional Recovery After Critical Illness (CORE-ICU)
Unraveling the Role of Cognitive Reserve, Inflammatory Phenotype and Genetic Vulnerability on Cognitive and Emotional Recovery After Critical Illness
Survivors of critical illness frequently develop persistent cognitive and emotional impairments, known as post-intensive care syndrome (PICS), which substantially impact quality of life and long-term recovery. While prior research has mainly focused on identifying risk factors, the mechanisms underlying resilience to these sequelae remain poorly understood. Emerging evidence suggests that biological factors, including inflammatory responses and genetic vulnerability, together with cognitive reserve, may play a key role in shaping recovery trajectories.
The aim of this multicenter, prospective observational study is to investigate how cognitive reserve, inflammatory phenotype, and genetic profiles interact to influence cognitive and emotional recovery after critical illness. Adult patients will be recruited at Intensive Care Unit (ICU) admission across two centers in Spain. Clinical and sociodemographic data will be collected during the ICU stay, and biological samples obtained early after admission will undergo transcriptomic and genetic analyses. Cognitive and emotional outcomes will be assessed at hospital discharge and at 3 and 12 months post-discharge using standardised neuropsychological and telemedicine-based evaluations.
By integrating clinical, biological, and cognitive data, this study seeks to identify recovery phenotypes and resilience mechanisms in PICS. The results may contribute to improved risk stratification, inform personalized interventions, and support the development of future strategies aimed at reducing the long-term burden of critical illness.
調査の概要
状態
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Sol Fernández-Gonzalo, PhD
- 電話番号：+34937236673
- メール：msfernandez@tauli.cat
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Adult patients (≥18 years)
- Admitted to a medical-surgical ICU or cardiac ICU for causes of critical illness (e.g., acute pulmonary oedema, myocardial infarction, aortic dissection)
- With or without the need for invasive mechanical ventilation
- With an expected ICU stay of ≥48 hours
- Resident in Catalonia or the Principality of Asturias
- Who speak Catalan and/or Spanish
- Who are able to provide informed consent personally or through an authorised representative (e.g., a family member)
Exclusion Criteria:
- Non-authorisation by the patient and/or relatives for inclusion in the study
- Patients admitted to a neurocritical ICU
- History of severe neurological disease (including dementia or focal brain injury with functional and cognitive impairment) prior to ICU admission
- History of severe psychiatric disorders (schizophrenia, bipolar disorder, major depressive disorder)
- Intellectual disability (IQ <80) or other neurodevelopmental disorders, such as autism spectrum disorder
- Patients who develop secondary complications (e.g., infections, stroke, traumatic brain injury, or other non-transient acquired brain injury) after ICU discharge that may compromise the results of emotional and neuropsychological evaluations during the recovery phase
- Moderate to severe cognitive impairment (Short-IQCODE >57) preventing independent participation in telemedicine or face-to-face follow-up
- Readmission to the ICU within 12 months after ICU discharge
- Language barrier (non-Spanish- and/or non-Catalan-speaking patients)
- Patients with a life expectancy <1 year or not eligible for active treatment measures
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Critically ill patients (Parc Taulí Hospital)
|
|
Critically ill patients (Hospital Universitario Central de Asturias)
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cognitive Reserve
時間枠：Within 24-48 hours after ICU discharge
|
Rami- Cognitive Reserve Questionnaire Score range: 0-25 Cognitive Reserve levels: Low: 0-6 Medium-low: 7-9 Medium-high: 10-14 |
Within 24-48 hours after ICU discharge
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Inflammatory phenotypes
時間枠：Within 24-48 hours of ICU admission
|
To characterize inflammatory and anti-inflammatory response phenotypes using transcriptomic and biomarker data
|
Within 24-48 hours of ICU admission
|
|
APOE genotype
時間枠：Within 24-48 hours of ICU admission
|
To characterize pathological aging mechanisims with APOE genotype
|
Within 24-48 hours of ICU admission
|
|
Level of consciousness
時間枠：During ICU stay (up to 28 days)
|
Measured using the Richmond Sedation-Agitation Scale (RASS) Score range: from -5 (unarousable) to +5 (agitated)
|
During ICU stay (up to 28 days)
|
|
Illness severity
時間枠：During ICU stay (up to 28 days)
|
Assessed using the Sequential Organ Failure Assessment (SOFA) questionnaire Score range: 0-24; 0-6: Mild organ dysfunction 7-9: Moderate severity 10-12: Significant organ dysfunction 13+: Severe illness with substantially increased mortality risk |
During ICU stay (up to 28 days)
|
|
Comorbidity burden
時間枠：During ICU stay (up to 28 days)
|
Measured using the Charlson Comorbidity Index (CCI) 0-1 point: Low comorbidity (absence of comorbidities or only very mild diseases). 2-3 points: Moderate to low comorbidity. 4 points or more: Severe comorbidity or high risk. |
During ICU stay (up to 28 days)
|
|
Frailty level
時間枠：During ICU stay (up to 28 days)
|
Assessed using the Rockwood Clinical Frailty Scale (CFS) Score range from 0 to 9; 1-3: Fit / Non-frail 4: Vulnerable / Very mild frailty 5: Mild frailty 6: Moderate frailty 7-8: Severe to very severe frailty 9: Terminal illness |
During ICU stay (up to 28 days)
|
|
Presence of delirium
時間枠：During ICU stay (up to 28 days)
|
Assessed using the Confusion Assessment Method for the ICU (CAM-ICU) Recorded as Yes/No
|
During ICU stay (up to 28 days)
|
|
Need and type of mechanical ventilation
時間枠：During ICU stay (up to 28 days)
|
Categorised as:
|
During ICU stay (up to 28 days)
|
|
Sedation treatment
時間枠：During ICU stay (up to 28 days)
|
Type of sedative agents administered:
|
During ICU stay (up to 28 days)
|
|
Benzodiazepine use
時間枠：During ICU stay (up to 28 days)
|
Recorded as Yes/No
|
During ICU stay (up to 28 days)
|
|
Global cognitive function (MoCA)
時間枠：At 3 months and 12 months after ICU discharge
|
Assessed using the Montreal Cognitive Assessment (MoCA) Score range: 0-30 Interpretation: 26-30 Normal cognitive function 18-25 Mild cognitive impairment (possible) 10-17 Moderate cognitive impairment <10 Severe cognitive impairment |
At 3 months and 12 months after ICU discharge
|
|
Attention and working memory
時間枠：At 3 months and 12 months after ICU discharge
|
Assessed using Digit Span Forward and Backward (WAIS-IV); Scaled score range: 1-19.
Higher scores indicate better performance; scores <8 suggest impairment.
|
At 3 months and 12 months after ICU discharge
|
|
Verbal memory
時間枠：At 3 months and 12 months after ICU discharge
|
Assessed using the Rey Auditory Verbal Learning Test (RAVLT); Total score range recall varies (typically 0-75).
Higher scores indicate better verbal learning and memory.
|
At 3 months and 12 months after ICU discharge
|
|
Processing speed
時間枠：At 3 months and 12 months after ICU discharge
|
|
At 3 months and 12 months after ICU discharge
|
|
Cognitive flexibility
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Trail Making Test Part B (TMT-B); measured in seconds.
Lower completion time indicates better performance.
|
At 3 and 12 months after ICU discharge
|
|
Inhibitory control
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Stroop Colour and Word Test.
Higher scores indicate greater impairment in inhibitory control.
|
At 3 and 12 months after ICU discharge
|
|
Verbal fluency
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Phonetic Fluency (FAS) Test; measured as the number of words generated.
Higher scores indicate better verbal fluency.
|
At 3 and 12 months after ICU discharge
|
|
Depression
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Patient Health Questionnaire-9 (PHQ-9). Score range 0-27; 0-4: None 5-9: Mild 10-14: Moderate 15-19: Moderately severe 20-27: Severe |
At 3 and 12 months after ICU discharge
|
|
Anxiety
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Generalized Anxiety Disorder-7 (GAD-7). Score range 0-21; 0-4: Minimal 5-9: Mild 10-14: Moderate 15-21: Severe |
At 3 and 12 months after ICU discharge
|
|
Post-traumatic stress disorder
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Treatment-Outcome Posttraumatic Stress Disorder Scale (TOP-8) Score range 0-32.
Higher scores indicate greater PTSD symptom severity.
|
At 3 and 12 months after ICU discharge
|
|
Perceived cognitive deficits
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Perceived Deficits Questionnaire (PDQ-D5).
Score range 0-20.
Higher scores indicate greater perceived cognitive impairment.
|
At 3 and 12 months after ICU discharge
|
|
Fatigue
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the FACIT Fatigue Scale (FACIT-F).
Score range 0-52.
Lower scores indicate greater fatigue, while higher scores indicate less fatigue.
|
At 3 and 12 months after ICU discharge
|
|
Pain
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Visual Analogue Scale (VAS-10). Score range 0-10; 0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe |
At 3 and 12 months after ICU discharge
|
|
Dyspnea
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Visual Analogue Scale (VAS-10). Score range 0-10; 0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe |
At 3 and 12 months after ICU discharge
|
|
Sleep quality
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Pittsburgh Sleep Quality Index (PSQI).
Score range 0-21.
Scores >5 indicate poor sleep quality.
|
At 3 and 12 months after ICU discharge
|
|
Resilience (post-traumatic growth)
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the Posttraumatic Growth Inventory (PTGI).
Score range 0-105.
Higher scores indicate greater post-traumatic growth.
|
At 3 and 12 months after ICU discharge
|
|
Quality of life
時間枠：At 3 and 12 months after ICU discharge
|
Assessed using the 12-Item Short Form Health Survey (SF-12).
Score range 0-100.
Higher scores indicate better health-related quality of life.
|
At 3 and 12 months after ICU discharge
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- PID2024-160948OA-I00
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data generated will be deposited in recognized open access repositories, accompanied by clear and standardized metadata, which will facilitate its discovery and reuse by other researchers (Institutional reference repository: CORA https://dataverse.csuc.cat/).
These measures not only ensure responsible treatment of data, but also guarantee their reuse and control
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。